Healthcare Biotechnology Takeaways From EHA

This report covers takeaways from the EHA conference for Syndax Pharmaceuticals (SNDX) and Geron Corporation (GERN). Data presented for SNDX’s revumenib and GERN’s Rytelo support their respective clinical profiles and ongoing development strategies.

Key Takeaways

• 1.SNDX presented encouraging clinical data for Revuforj (revumenib) at EHA, strengthening the case for its use in frontline and combination settings for AML.
• 2.GERN reported real-world evidence of Rytelo efficacy consistent with clinical trials in a heavily pretreated myelodysplastic syndrome population.

Table of Contents

• Healthcare: Biotechnology: Takeaways from EHA
• SNDX: revumenib datasets add confidence to combination/frontline use-case
• GERN: real-world data reinforces clinical efficacy of Rytelo in pre-treated population
• Valuation and risks
• Disclosure Appendix

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial